VivaMed

What VivaMed does

VivaMed BioPharma is a privately held AI-driven precision drug discovery company developing therapeutics for chronic neurological, psychiatric, pain, pulmonary, and rheumatologic conditions. The company is headquartered in Scottsdale, Arizona, with the legal entity VivaMed BioPharma, Inc. incorporated in Delaware. Its proprietary BioAtlas Platform applies AI to generate therapeutic hypotheses for both drug repurposing and new chemical entity development, emphasizing mechanism-grounded analysis and biomarker enrichment.

The company's pipeline includes over 50 active drug assets, with disclosed first-in-class candidates such as VM-PAIN-003 (a non-opioid small molecule for trigeminal neuralgia supported by a CRADA with NIH NCATS under the HEAL Initiative), VM-NEU-001 (a neurosteroid for Parkinson's Disease), VM-NEU-002 (a disease-modifying Alzheimer's candidate), VM-NEU-003 (refractory epilepsy), and VM-PAIN-001 (an oral prolonged-release ketamine for CRPS). The company cites 39 prior regulatory approvals across its history and maintains therapeutic focus on five areas of unmet need.

VivaMed generates revenue through licensing agreements, co-development partnerships, and risk-sharing structures with pharmaceutical companies, biotech firms, academic medical centers, and patient foundations. It operates from five offices across three continents (Phoenix, New York, Basel, Bogotá, Riyadh) and in February 2026 entered a strategic collaboration with Syngene International for preclinical execution. The company is led by Founder & CEO Kendric Speagle with an executive team of 8 and a broader team of approximately 28 including 14 clinical advisors.

Name

VivaMed

Legal name

VivaMed BioPharma, Inc.

Website

https://vivamed.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

VivaMed BioPharma is an AI-driven precision drug discovery company that uses its BioAtlas Platform to develop 50+ therapeutic candidates across neurology, pain, psychiatry, pulmonology, and rheumatology, monetized through licensing and co-development partnerships with pharma, biotech, academic centers, and patient foundations.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Discovery and Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Precision drug discovery
• AI-driven drug repurposing
• Biopharmaceutical pipeline development
• Neuropathic pain therapeutics
• Pharmaceutical licensing partnerships

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and co-development: Revenue generated through licensing drug assets to pharmaceutical partners, co-development agreements, and risk-sharing structures. Partners can access detailed program information under CDA.
2. Drug asset development: Development and advancement of 50+ active drug assets from discovery through regulatory approval, with 39 prior regulatory approvals demonstrating track record.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

VivaMed BioPharma develops and licenses a portfolio of 50+ active drug assets spanning Neurology, Pain Management, Psychiatry, Pulmonology, and Rheumatology. The company combines its AI-driven BioAtlas Platform — which generates mechanism-grounded therapeutic hypotheses for precision drug repurposing — with translational and preclinical development to deliver first-in-class candidates such as VM-NEU-001, VM-NEU-002, VM-NEU-003, VM-PAIN-001, and VM-PAIN-003 to pharmaceutical, biotech, and academic partners via licensing and co-development.

Product overview

VivaMed BioPharma operates as an AI-driven precision drug discovery company built around its BioAtlas Platform. The platform enables computational drug identification and repurposing, combining AI-generated therapeutic hypotheses with clinical validation. The company's pipeline includes over 50 active drug assets spanning five therapeutic areas (Neurology, Pain Management, Psychiatry, Pulmonology, Rheumatology), including first-in-class candidates such as VM-NEU-001 (neurosteroid for Parkinson's Disease), VM-NEU-002 (Alzheimer's Disease modifier), VM-PAIN-001 (modified-release ketamine for CRPS), and VM-PAIN-003 (trigeminal neuralgia therapeutic). The pipeline ranges from new chemical entities to repurposed drugs, with assets progressing through discovery, preclinical, and clinical phases.

Differentiator

Problem solved

Functional benefit

Products and services

• BioAtlas Platform AI-driven drug discovery platform enabling precision drug repurposing through mechanism-grounded analysis and biomarker enrichment, producing therapeutic hypotheses that feed directly into preclinical development.
• VM-NEU-001

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Syngene InternationalcoreStrategic or Co-development Partner · 20 February 2026Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI-derived repurposed therapeutic programs. The partnership combines Syngene's preclinical development expertise with VivaMed's AI-generated therapeutic hypotheses, creating a direct pipeline from computational drug identification to translational and experimental validation. Both companies aim to create a scalable infrastructure for partnership-focused therapeutic candidates targeting pharmaceutical collaboration.
• NIH National Center for Advancing Translational Sciences (NCATS) - HEAL InitiativecoreStrategic or Co-development PartnerThe VM-PAIN-003 (Trigememinal Neuralgia) program is supported by a Cooperative Research and Development Agreement (CRADA) with the NIH National Center for Advancing Translational Sciences (NCATS) as part of the HEAL Initiative. This supports the non-opioid analgesic development program targeting severe neuropathic pain without addiction liability.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Insitro: Machine-learning-enabled drug discovery company combining induced pluripotent stem cell biology with AI. Comparable in applying AI to de novo therapeutic hypothesis generation and preclinical pipeline expansion.
• Lantern Pharma: AI-driven precision oncology company using its RADR platform to identify and develop repurposed and novel drug candidates. Similar asset-light, platform-enabled development model with multiple programs.
• BioXcel Therapeutics: AI-driven pharmaceutical company applying machine learning to approved drugs for new indications in neuroscience and immuno-oncology. Comparable repurposing-first strategy with CNS focus.
• Atomwise: AI-driven small molecule drug design platform with partnership-driven pipeline across multiple therapeutic areas. Closely matches VivaMed's licensing and co-development GTM motion.
• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Most directly comparable to VivaMed's BioAtlas approach, though Recursion operates at significantly larger scale post-Exscientia merger.
• BenevolentAI: AI-powered drug discovery company leveraging knowledge graphs and ML to identify novel therapeutic targets. Comparable in repurposing/positioning assets for partnership with larger pharma.

Emerging players

• Pharnext: Drug repurposing company combining approved drugs in novel combinations for CNS and rare diseases. Comparable repurposing-led approach targeting underserved neurology indications.
• Standigm: AI-driven drug discovery company with proprietary pipelines and partnership-based model across multiple therapeutic areas. Closely aligned with VivaMed's platform-and-partnerships approach at similar scale.

Broad incumbents

• Axsome Therapeutics: Commercial-stage CNS specialty pharma with marketed products in depression and migraine. Comparable CNS therapeutic focus and demonstrates the upside trajectory VivaMed's pain/neuro assets could pursue.
• Intra-Cellular Therapies: CNS-focused pharma commercialized Caplyta across multiple neuropsychiatric indications. Comparable CNS-first focus and represents an incumbent whose scope VivaMed's pipeline aspires to match.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vivamed-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VivaMed